Home › Companies › PMV Pharmaceuticals, Inc. › 2025-2026
At PMV Pharmaceuticals, Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 59 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 170 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — PMV Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 70% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: PMV Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 5, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and PMV Pharmaceuticals, Inc.’s Form 8-K, filed June 5, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 4, 2026: 4 items on PMV Pharmaceuticals, Inc.’s Form 8-K, filed June 5, 2026: 2 elected · 2 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore PMV Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are PMV Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: David H. Mack, Ph.D. | 15,693,907 | -- | -- | 6,248,461 | 6,975,412 | 72% | Elected | — |
| Elect Director: Laurie Stelzer | 11,261,111 | -- | -- | 10,681,257 | 6,975,412 | 51.3% | Elected | — |
| 2. Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers | 15,015,578 | 6,468,718 | 458,072 | -- | 6,975,412 | 70% | Approved | — |
| 3. Ratification of Independent Registered Public Accounting Firm | 28,379,108 | 536,302 | 2,370 | -- | -- | 98% | Approved | — |
Source: PMV Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 5, 2026 — read the filing on EDGAR.
Each item below shows how the 59 asset managers that disclosed a PMV Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
72% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: David H. Mack, Ph.D.
PMV Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David H. Mack, Ph.D.”): 15,693,907 for, 6,248,461 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the two persons listed below as Class III Directors, each to serve until the Company's 2029 annual meeting of stockholders and until their respective successors has been duly elected and qualified, or until the earlier of the respective direc…”
Support: 72% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 16 asset managers below reported 3,622,362 for, 510,513 withheld, 14 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,938,211 | 0 | 14 | 2,901 | For |
| MERIDIAN FUND INC | 1,056,713 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 408,353 | Withhold |
| Fidelity | 407,977 | 0 | 0 | 0 | For |
| BlackRock | 107,052 | 0 | 0 | 0 | For |
| Goldman Sachs | 74,321 | 0 | 0 | 0 | For |
| Nationwide | 0 | 0 | 0 | 69,995 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 16,133 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 13,237 | 0 | 0 | 0 | For |
| GuideStone | 0 | 0 | 0 | 12,058 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 11,700 | Withhold |
| Equitable | 8,718 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 4,716 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 356 | Withhold |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 278 | Withhold |
| Guggenheim | 0 | 0 | 0 | 156 | Withhold |
Combines 4 wordings of this item as funds reported it.
51.3% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Laurie Stelzer
PMV Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Laurie Stelzer”): 11,261,111 for, 10,681,257 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the two persons listed below as Class III Directors, each to serve until the Company's 2029 annual meeting of stockholders and until their respective successors has been duly elected and qualified, or until the earlier of the respective direc…”
Support: 51.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 16 asset managers below reported 2,419,117 for, 1,590,562 withheld, 123,210 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,936,819 | 0 | 25 | 4,282 | For |
| MERIDIAN FUND INC | 0 | 0 | 0 | 1,056,713 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 408,353 | Withhold |
| Fidelity | 407,977 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 107,052 | 0 | Abstain |
| Goldman Sachs | 74,321 | 0 | 0 | 0 | For |
| Nationwide | 0 | 0 | 0 | 69,995 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 16,133 | 0 | Abstain |
| Columbia Threadneedle | 0 | 0 | 0 | 13,237 | Withhold |
| GuideStone | 0 | 0 | 0 | 12,058 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 11,700 | Withhold |
| Equitable | 0 | 0 | 0 | 8,718 | Withhold |
| American Century | 0 | 0 | 0 | 4,716 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 356 | Withhold |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 278 | Withhold |
| Guggenheim | 0 | 0 | 0 | 156 | Withhold |
Combines 5 wordings of this item as funds reported it.
70% Approved · of votes cast
Description as filed by funds: APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
PMV Pharmaceuticals, Inc.’s own tally for this item (“2. Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers”): 15,015,578 for, 6,468,718 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on a non-binding advisory basis, the compensation paid to its named executive officers as described in the Company's definitive proxy statement on Schedule 14A, filed…”
Support: 70% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,941,110 | 15 | 1 | 0 | For |
| MERIDIAN FUND INC | 1,056,713 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 408,353 | 0 | 0 | Against |
| Fidelity | 407,977 | 0 | 0 | 0 | For |
| BlackRock | 107,052 | 0 | 0 | 0 | For |
| Goldman Sachs | 74,321 | 0 | 0 | 0 | For |
| Nationwide | 0 | 69,995 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 16,133 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 13,237 | 0 | 0 | Against |
| GuideStone | 0 | 12,058 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 11,700 | 0 | 0 | Against |
| Equitable | 8,718 | 0 | 0 | 0 | For |
| American Century | 0 | 4,716 | 0 | 0 | Against |
| Lincoln Financial | 0 | 356 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 278 | 0 | 0 | 0 | For |
| Guggenheim | 0 | 156 | 0 | 0 | Against |
Fund voting reports, all 16 managers: 3,612,302 for, 520,586 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Eversept Partners, LP | 0 | 0 | 1,986,405 | 0 | Abstain |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 1,860,000 | 0 | 0 | Against |
| Two Sigma | 0 | 1,770,090 | 0 | 0 | Against |
| ArrowMark Colorado Holdings LLC | 1,686,663 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 0 | 1,590,771 | 0 | 0 | Against |
| Stonepine Capital Management, LLC | 708,102 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 495,922 | 0 | 0 | 0 | For |
| Aldebaran Capital, LLC | 471,262 | 0 | 0 | 0 | For |
| BlackRock | 455,963 | 93 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 428,853 | 0 | 0 | Against |
| Invesco | 360,786 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 353,632 | 0 | 0 | 0 | For |
| Vanguard | 319,685 | 316 | 0 | 0 | For |
| MARSHALL WACE, LLP | 254,149 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 231,008 | 0 | 0 | 0 | For |
| BBR PARTNERS, LLC | 200,000 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 190,855 | 0 | 0 | 0 | For |
| State Street | 177,152 | 6,026 | 0 | 0 | For |
| Velan Capital Investment Management LP | 73,000 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 53,874 | 0 | 0 | Against |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0 | 53,305 | 0 | 0 | Against |
| ALGERT GLOBAL LLC | 37,085 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | 32,394 | 0 | 0 | Against |
| Point72 | 0 | 20,709 | 0 | 0 | Against |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 0 | 19,734 | 0 | 0 | Against |
Institutional-manager reports, all 45 managers: 6,089,774 for, 5,849,177 against, 1,986,405 abstained. Showing the 25 largest; every one is in the interactive database (link above).
98% Approved · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT PUBLIC ACCOUNTING FIRM.
PMV Pharmaceuticals, Inc.’s own tally for this item (“3. Ratification of Independent Registered Public Accounting Firm”): 28,379,108 for, 536,302 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 16 asset managers below reported 4,132,888 for, 1 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,941,125 | 1 | 0 | 0 | For |
| MERIDIAN FUND INC | 1,056,713 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 408,353 | 0 | 0 | 0 | For |
| Fidelity | 407,977 | 0 | 0 | 0 | For |
| BlackRock | 107,052 | 0 | 0 | 0 | For |
| Goldman Sachs | 74,321 | 0 | 0 | 0 | For |
| Nationwide | 69,995 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 16,133 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 13,237 | 0 | 0 | 0 | For |
| GuideStone | 12,058 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 11,700 | 0 | 0 | 0 | For |
| Equitable | 8,718 | 0 | 0 | 0 | For |
| American Century | 4,716 | 0 | 0 | 0 | For |
| Lincoln Financial | 356 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 278 | 0 | 0 | 0 | For |
| Guggenheim | 156 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 53,331,766 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.64% |
| 2 | MERIDIAN FUND INC | 1.98% |
| 3 | BRIDGEWAY FUNDS INC | 0.77% |
| 4 | Fidelity | 0.76% |
| 5 | BlackRock | 0.20% |
| 6 | Goldman Sachs | 0.14% |
| 7 | Nationwide | 0.13% |
| 8 | MASTER INVESTMENT PORTFOLIO | 0.03% |
| 9 | Columbia Threadneedle | 0.02% |
| 10 | GuideStone | 0.02% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Eversept Partners, LP | 3.72% |
| 2 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.49% |
| 3 | Two Sigma | 3.32% |
| 4 | ArrowMark Colorado Holdings LLC | 3.16% |
| 5 | ACADIAN ASSET MANAGEMENT LLC | 2.98% |
| 6 | Stonepine Capital Management, LLC | 1.33% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 0.93% |
| 8 | Aldebaran Capital, LLC | 0.88% |
| 9 | BlackRock | 0.86% |
| 10 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.80% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Srinivas Akkaraju | 14.21% | 13G |
| BML Investment Partners, L.P. | 9.92% | 13G |
| Entities affiliated with Tang Capital Management, LLC | 8.85% | DEF14A |
| David H. Mack, Ph.D. | 5.23% | DEF14A |
| Sio Capital Management, LLC | 4.94% | 13G |
| Euclidean Capital LLC | 4.93% | 13G |
| Vanguard Group | 4.07% | 13F |
| ArrowMark Colorado Holdings, LLC | 3.67% | 13G |
| Two Sigma | 3.53% | 13F |
| BlackRock | 1.64% | 13F |
Percentages above are of 53,331,766 shares outstanding, as reported by PMV Pharmaceuticals, Inc. on its Form 10-Q dated May 12, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PMV Pharmaceuticals, Inc.’s 10-Q dated May 12, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
PMV Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
proxyvotesnow.com, “PMV Pharmaceuticals (PMVP) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/pmv-pharmaceuticals-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.